Centro de Aprendizagem Explore recursos que o ajudam a compreender e gerir a artrite psoriática. Learning hub Factos‑chave Guia Doente Notícias Quizzes Pesquisar Feed RSS de Notícias Artigos sobre Artrite Psoriática na Nature Reviews Rheumatology Journal of Psoriasis and Psoriatic Arthritis National Psoriasis Foundation

Equipe de especialistas clínicos Gail Heritage University of Oxford Position Senior Research Manager What is your role in iPROLEPSIS? UK PDPID coordinating center Manager What are your main activities in the project? UK Study manager What is your motivation? Contribution to clinical research to enhance patient experiences and disease outcomes. Francesca Levi-Schaffer The Hebrew University of Jerusalem, Israel Position Professor What is your role in iPROLEPSIS? Researcher What are your main activities in the project? To try to understand the passage from psoriasis to psoriatic arthritis by evaluating in skin biopsies vascularization, mast cell presence and to correlate this with involved joint vascularization What is your motivation? I would like to discover the connections between skin and joints and find a drug/s that can inhabit this progression Laura Coates Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Position NIHR Research Professor What is your role in iPROLEPSIS? Lead for WP5 (clinical studies) What are your main activities in the project? I oversee all of the clinical studies within the consortium. What is your motivation? I am a rheumatologist who has worked in research in psoriatic arthritis for around 20 years. My interest is in improving outcomes for people living with psoriatic arthritis and I believe that work in this project can help us to predict, monitor and understand the disease better in day to day clinics. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Centro de Aprendizagem Explore recursos que o ajudam a compreender e gerir a artrite psoriática. Learning hub Factos‑chave Guia Doente Notícias Quizzes Pesquisar Manual da Artrite Psoriática Viver com Artrite Psoriática Handbook Como é que a artrite psoriática me vai afetar? TRABALHO O trabalho pode proporcionar um sentido de propósito, identidade, realização e uma rede social de apoio, contribuindo positivamente para o seu bem-estar emocional e físico. Embora a sua condição possa colocar alguns desafios, as pessoas que vivem com artrite psoriática podem continuar a trabalhar, desde que a sua profissão não agrave os sintomas e não piore a sua saúde. As pessoas com determinadas condições de saúde têm direitos definidos na lei, destinados a protegê-las contra a discriminação direta e indireta no local de trabalho. O seu empregador é legalmente obrigado a fazer “adaptações razoáveis” ao seu ambiente e práticas de trabalho para garantir que a sua condição não o impede de fazer o seu trabalho da melhor forma possível e num ambiente confortável e seguro. h3.1 Na União Europeia, a definição de adaptações razoáveis no trabalho foi introduzida pelo artigo 5.º da Diretiva relativa à igualdade de tratamento no emprego e na atividade profissional (Diretiva 2000/78/CE): “a entidade patronal toma, para o efeito, as medidas adequadas, em função das necessidades numa situação concreta, para que uma pessoa deficiente tenha acesso a um emprego, o possa exercer ou nele progredir, ou para que lhe seja ministrada formação, exceto se essas medidas implicarem encargos desproporcionados para a entidade patronal. Os encargos não são considerados desproporcionados quando forem suficientemente compensados por medidas previstas pela política do Estado-Membro em causa em matéria de pessoas deficientes”. Esta diretiva foi transposta para a legislação nacional em todos os Estados-Membros da UE. Estudos demonstraram que as pessoas que necessitam de adaptações no local de trabalho e que as utilizam efetivamente têm mais probabilidades de manter um emprego e de continuar a ser produtivas, do que as que não utilizam adaptações no local de trabalho (39). No entanto, pedir adaptações no local de trabalho pode ser difícil. Pode preocupar-se com a possibilidade de ter um tratamento diferente e com as reações negativas do(s) seu(s) supervisor(es) ou colega(s). Por este motivo, pode preferir negociar adaptações informais no local de trabalho em vez de procurar adaptações formais. Algumas destas adaptações podem incluir as apoiadas pelas recomendações do American College of Sports Medicine para a atividade física e a saúde pública (40) e a norma ISO 11226, https://www.iso.org/standard/25573.html , que definem os limites para salvaguardar a saúde musculosquelética. Ao alinharem as práticas no local de trabalho com estas recomendações cientificamente comprovadas, os empregadores e os profissionais de saúde podem responder melhor às necessidades dos seus trabalhadores, promovendo um ambiente de trabalho inclusivo e solidário. Seguem-se alguns exemplos: Recomendação n.º 1: Evitar trabalhar durante períodos prolongados na mesma posição, quer esteja sentado ou de pé. Durante o turno de trabalho: um período contínuo de tempo na posição de pé não deve exceder 1 hora; o tempo total passado numa posição de pé não deve exceder 4 horas; a permanência contínua na posição sentada deve ser limitada a 2 horas; quando os períodos são dedicados à realização de reuniões, cuja duração deve ser razoável, deve ser considerada a possibilidade de as realizar de pé ou a andar (41). Recomendação n.º 2: Fazer pausas frequentes ao longo do turno. Note-se que a definição de “pausas” deve ter em conta as seguintes características: frequência: número de pausas/interrupções durante o dia de trabalho; duração: micro-pausas (menos de 2 minutos); pausas curtas (normalmente as que ocorrem de manhã ou à tarde, com duração entre 7 e 10 minutos); ou pausas longas (pausas para refeições); e tipo: passivo ou em repouso e ativo (incluindo alongamentos ou caminhadas) (42). Assim, num dia de trabalho de 8 horas, um trabalhador deve fazer pelo menos uma pausa de 7 a 10 minutos após períodos de trabalho consecutivos de 90 minutos. Os períodos de recuperação podem incluir momentos de descanso ou a realização de qualquer outra tarefa para recuperar os grupos musculares que foram trabalhados. Num período de pelo menos 90 minutos, um trabalhador deve gozar pelo menos 30 segundos após cada 20 minutos de trabalho. Ambas as recomendações têm como objetivo abordar a exposição prolongada a cargas estáticas de baixa intensidade, limitando a duração dessa exposição. Estas intervenções ajudam a aliviar a fadiga e os sintomas de dor a curto prazo e a prevenir lesões musculosqueléticas relacionadas com o trabalho a longo prazo. As pausas ativas são uma mais-valia; no entanto, não substituem a necessidade de introduzir diversidade na intensidade da carga mecânica, como planos de rotação adequados às exigências do trabalho (43). Note-se que estas recomendações se referem a tarefas de baixa intensidade e fisicamente exigentes. Outras recomendações aplicam-se a tarefas de alta intensidade, como as que envolvem força manual. Recomendação n.º 3: Alterações físicas nos postos de trabalho superfícies de trabalho (secretárias) que permitam alternar entre estar de pé e estar sentado, isoladamente ou em combinação com um programa de formação e informação para os trabalhadores, reduzem o tempo sentado em cerca de 60 minutos por dia de trabalho (a médio prazo, ou seja, até 3-12 meses). Esta alteração das condições físicas de trabalho pode provocar uma mudança de comportamento, com repercussões numa redução média de 82 minutos no tempo total de permanência sentado por dia (no trabalho e fora dele) e na duração média dos períodos consecutivos de permanência sentado (57 minutos) (42, 44). Apesar de as adaptações no local de trabalho estarem consignadas no Código do Trabalho português, muitas pessoas com doenças reumáticas e musculosqueléticas referem falta de compreensão por parte do(s) seu(s) empregador(es), colega(s) e médico(s) do trabalho. Tem opções e direitos; é importante compreendê-los e explorar plenamente todas as alternativas disponíveis. Se não tem a certeza dos seus direitos no local de trabalho, contacte o seu sindicato ou um advogado. Em Portugal existe legislação que protege os direitos dos trabalhadores com deficiência ou doença crónica. Se necessitar de adaptações no local de trabalho, fale com o seu médico assistente sobre as dificuldades que tem sentido e peça relatórios para apresentar à sua entidade patronal e/ou ao médico do trabalho. Ver secção correspondente no Informações Essenciais SONO A dor, a ansiedade e os efeitos secundários da medicação podem dificultar o adormecer e a manutenção do sono durante a noite. De fato, cerca de 40% das pessoas que vivem com artrite psoriática referem dificuldades em dormir (45). Bons hábitos de higiene do sono podem ajudar a melhorar o sono: desenvolva uma rotina de sono regular, ou seja, deite-se e levante-se à mesma hora todos os dias; evite cafeína, álcool e grandes refeições antes de se deitar; se fuma, tente deixar de fumar ou, pelo menos, não fume perto da hora de deitar; um banho quente antes de se deitar pode ajudar a aliviar a dor e a rigidez; ouça música ou sons relaxantes antes de ir para a cama; evite ver televisão e utilizar computadores, tablets ou smartphones no seu quarto; certifique-se de que o seu quarto está escuro, silencioso, relaxante e tem uma temperatura confortável. h3.2 O impacto da prática de exercício físico antes de deitar pode variar consoante os indivíduos. É essencial ouvir o seu corpo, estabelecer uma rotina consistente e prestar atenção à forma como os exercícios noturnos afetam os seus padrões de sono. Se tiver preocupações específicas sobre o seu sono ou rotina de exercício, também é aconselhável consultar um profissional de saúde ou um especialista em fitness. Prós: Melhoria da qualidade do sono: For some people, engaging in moderate-intensity exercises a few hours before bedtime may promote better sleep quality. It can help reduce stress and anxiety, leading to a more relaxed state conducive to sleep. Regulação da temperatura corporal: o exercício físico aumenta a temperatura corporal e a subsequente descida da temperatura após o exercício pode sinalizar ao organismo que é altura de dormir. Isto imita a descida natural da temperatura que ocorre durante a noite. Estabelecer uma rotina: o exercício regular, independentemente da altura do dia, pode contribuir para uma melhor qualidade do sono. O estabelecimento de uma rotina de exercício consistente é muitas vezes mais importante do que a hora específica do dia. Contras Efeito estimulante: para algumas pessoas, o exercício intenso perto da hora de deitar pode ter um efeito estimulante, tornando mais difícil relaxar e adormecer. Temperatura corporal: embora a descida da temperatura corporal após o exercício possa promover o sono, o exercício demasiado próximo da hora de deitar pode perturbar o processo natural de arrefecimento do corpo, interferindo potencialmente com o sono. Variabilidade individual: as pessoas reagem de forma diferente ao horário do exercício. Algumas podem achar que os treinos noturnos não afetam o seu sono, enquanto outras podem ter dificuldades. Recomendações: O tempo é importante: tente terminar o exercício pelo menos 2 a 3 horas antes de se deitar, para permitir que a temperatura do seu corpo volte ao normal e que os seus níveis de adrenalina diminuam. Ouça o seu corpo: preste atenção à forma como o seu corpo reage aos treinos noturnos. Poderá ser uma boa opção para si se o ajudar a relaxar e a melhorar o seu sono. Experiência: cada pessoa é diferente. Experimente horários diferentes de exercício para ver o que funciona melhor para si. Se os treinos noturnos tiverem um impacto negativo no seu sono, considere mudá-los para mais cedo. A moderação é fundamental: o exercício intenso ou vigoroso perto da hora de deitar pode interferir mais com o sono. Opte por atividades de intensidade moderada à noite (47). Cerca de 50% dos doentes que sofrem de artrite psoriática referem níveis elevados de fadiga (cinco ou mais numa escala de 10 pontos) e consideram a fadiga como um dos principais problemas, a seguir às dores articulares e antes dos problemas de pele (48). Ver secção correspondente no Informações Essenciais FADIGA A resolução de problemas, o planeamento, a definição de prioridades e do seu ritmo podem ajudar a lidar melhor com a sua fadiga: RESOLUÇÃO DE PROBLEMAS identifique os fatores / tarefas / atividades que contribuem para a sua fadiga; pense em soluções que possam ajudar a minimizar o impacto destes fatores / tarefas / atividades. PLANEAMENTO planeie as tarefas/atividades que pretende realizar num dia ou numa semana; certifique-se de que inclui atividades de que gosta e que podem melhorar a sua disposição/bem-estar; não se martirize se não conseguir cumprir o plano. DEFINIÇÃO DE PRIORIDADES organize as suas tarefa/atividades por ordem de importância. RITMO não utilize a sua energia de uma só vez; divida as tarefas/atividades planeadas em porções mais pequenas que podem ser distribuídas ao longo de um dia, uma semana ou mesmo mais tempo. Ver secção correspondente no Informações Essenciais BEM-ESTAR EMOCIONAL Viver com artrite psoriática pode afetar a sua saúde mental (49, 50). É necessário tratar os sintomas de saúde mental com a mesma seriedade que os sintomas físicos. Uma saúde mental deficiente pode provocar crises de artrite psoriática, aumentar a dor e a fadiga, afetar negativamente o trabalho e as relações pessoais e limitar a capacidade de gerir a saúde em geral. Se se sentir triste, sem esperança e perder o interesse por coisas que costumava gostar, fale com o seu médico e informe os seus familiares sobre o que está a passar. O seu médico pode fazer o encaminhamento para serviços de saúde mental, como a terapia cognitivo-comportamental (TCC) e/ou pode receitar-lhe um antidepressivo. h3.3 h3.4 Lembre-se de que não está só. Se precisar de apoio adicional, estamos aqui para o ajudar: Serviço de Aconselhamento Psicológico da Linha SNS 24 808 24 24 24 Linha SOS Voz Amiga 213 544 545 912 802 669 ou 963 524 660 Seja gentil com as suas articulações e com a sua mente Ver secção correspondente no Informações Essenciais Informações Essenciais Página anterior Próxima página

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

Download needed deliverables for iProlepsis project for psoriatic arthritis. Entregáveis D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Ler mais D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Ler mais D3.1 First report on PsA inflammation drivers research WP3 - Research on PsA inflammation drivers and monitoring Ler mais D4.4 The iPROLEPSIS serious gaming suite (alpha version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Ler mais D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Ler mais D6.8 Update on the Dissemination, Exploitation and Communication Plan WP6 - Dissemination, communication and exploitation Ler mais D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Ler mais D2.4 Updated report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Ler mais D3.2 First report on digital phenotyping for PsA WP3 - Research on PsA inflammation drivers and monitoring Ler mais D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Ler mais D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Ler mais D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Ler mais D2.5 Updated report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Ler mais D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Ler mais D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Ler mais D6.5 Midterm report on project visibility and educational material WP6 - Dissemination, communication and exploitation Ler mais

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Introduction Learning how to live with psoriatic arthritis might feel like a challenge, especially at first. But understanding your diagnosis and how to manage this chronic disease can help you take control of your health. Psoriatic arthritis patient booklet is meant to help you understand your disease and medications, and to improve your ability to communicate your symptoms and concerns to your healthcare professionals. Here, you will also find several non-pharmacological strategies that may ease your symptoms and help you to cope with this disease (e.g., physical exercise, sleeping habits, and diet). This booklet has been edited by rheumatologists, healthcare experts, and patients living with psoriatic arthritis. The information in this booklet is for educational purposes only, and it should never replace the information and advice from your treating physician(s). It is meant to inform the discussions that you have with healthcare professionals, as well as others who play a role in your care and well-being. What is psoriatic arthritis? Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is characterized by joint swelling (inflammation), pain and stiffness and can affect any peripheral joint such as fingers, toes, knees and/or spine. It also affects the insertion of tendons or ligaments in bones (enthesitis). Between 20-40% of people with the skin condition psoriasis will develop psoriatic arthritis. Symptoms affecting their joints tend to develop 5 to 10 years after psoriasis is diagnosed but it can occur at any time. Currently, it is not clear why some people with psoriasis develop psoriatic arthritis while others do not. The arthritis of psoriatic arthritis comes in three forms: oligoarticular arthritis that affects four or less peripheral joints (e.g., joints in the fingers, toes, knees); polyarticular arthritis that involves five or more peripheral joints on both sides of the body; and axial arthritis that affects the joints of the spine including the sacroiliac joint (where the spine connects to the pelvis). Some people may develop psoriasis after or at the same time as symptoms of psoriatic arthritis present themselves (4). In rare cases, people may have psoriatic arthritis and never have any noticeable symptoms of psoriasis. Psoriatic arthritis and psoriasis are chronic inflammatory conditions that are caused by a fault in the immune system. Our immune system protects us from infection and illness. Learn about psoriatic arthritis Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 The Psoriatic Arthritis Patient Handbook is now available for download. The booklet includes essential information to support your understanding of psoriatic arthritis and offers practical tips to enhance your daily life.

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts Keyfacts 1 What is Psoriatic Arthritis? See related Handbook section What Causes Psoriatic Arthritis? See related Handbook section What Are The Symptoms? See related Handbook section Psoriatic Arthritis Handbook Search Search News Feed

Learning how to live with psoriatic arthritis might feel like a challenge. But understanding your diagnosis can help you take control of your health. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Learning hub Key Facts Handbook News Feed Quizzes Search Quizzes What is Psoriatic Arthritis? Take a Quiz What Are The Symptoms? Key Facts What Causes Psoriatic Arthritis? Key Facts

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 Learning how to live with psoriatic arthritis might feel like a challenge, especially at first. But understanding your diagnosis and how to manage this chronic disease can help you take control of your health. Psoriatic arthritis patient booklet is meant to help you understand your disease and medications, and to improve your ability to communicate your symptoms and concerns to your healthcare professionals. Here, you will also find several non-pharmacological strategies that may ease your symptoms and help you to cope with this disease (e.g., physical exercise, sleeping habits, and diet). This booklet has been edited by rheumatologists, healthcare experts, and patients living with psoriatic arthritis. The information in this booklet is for educational purposes only, and it should never replace the information and advice from your treating physician(s). It is meant to inform the discussions that you have with healthcare professionals, as well as others who play a role in your care and well-being. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is characterized by joint swelling (inflammation), pain and stiffness and can affect any peripheral joint such as fingers, toes, knees and/or spine. It also affects the insertion of tendons or ligaments in bones (enthesitis). Between 20-40% of people with the skin condition psoriasis will develop psoriatic arthritis. Symptoms affecting their joints tend to develop 5 to 10 years after psoriasis is diagnosed but it can occur at any time. Currently, it is not clear why some people with psoriasis develop psoriatic arthritis while others do not. The arthritis of psoriatic arthritis comes in three forms: oligoarticular arthritis that affects four or less peripheral joints (e.g., joints in the fingers, toes, knees); polyarticular arthritis that involves five or more peripheral joints on both sides of the body; and axial arthritis that affects the joints of the spine including the sacroiliac joint (where the spine connects to the pelvis). Some people may develop psoriasis after or at the same time as symptoms of psoriatic arthritis present themselves (4). In rare cases, people may have psoriatic arthritis and never have any noticeable symptoms of psoriasis. Psoriatic arthritis and psoriasis are chronic inflammatory conditions that are caused by a fault in the immune system. Our immune system protects us from infection and illness. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 The Psoriatic Arthritis Patient Handbook is now available for download. The booklet includes essential information to support your understanding of psoriatic arthritis and offers practical tips to enhance your daily life.